Royalty Pharma (RPRX) Receivables - Other (2019 - 2023)

Royalty Pharma has disclosed Receivables - Other across 5 years of filings, most recently posting $14.2 million for Q4 2023.

• Receivables - Other for Q4 2023 came in at $14.2 million, down 15.38% year-over-year; the trailing twelve-month figure through Dec 2023 was $14.2 million (down 15.38% YoY), and the FY2023 annual result was $14.2 million, changed N/A from the prior year.
• Receivables - Other came in at $14.2 million for Q4 2023 at Royalty Pharma, down from $16.4 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $59.7 million in Q3 2021 to a low of $14.2 million in Q4 2023.
• The 5-year median for Receivables - Other is $32.3 million (2020), against an average of $29.8 million.
• Across the five-year window, Receivables - Other surged 84.29% in 2021 and slumped 73.66% in 2022, its largest moves.
• Royalty Pharma's Receivables - Other stood at $33.5 million in 2019, then retreated by 1.1% to $33.2 million in 2020, then soared by 60.72% to $53.3 million in 2021, then sank by 68.42% to $16.8 million in 2022, then declined by 15.38% to $14.2 million in 2023.
• The last three Receivables - Other figures came in at $14.2 million (Q4 2023), $16.4 million (Q3 2023), and $16.4 million (Q2 2023), per Business Quant data.